Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Presence of ≥ 1 measurable pulmonary nodule (1.0-3.0 cm) suggestive of malignancy or chronic inflammatory process on positron emission tomography (PET) scan
• •No lesions consistent with malignancy or inflammation according to history, PET findings, or biopsy
• •Baseline scan average time between injection and start of scan within 50-70 min
• •* Mean liver standardized uptake value (SUV) of baseline scan normal
• •* No sign of significant partial paravenous tracer administration in the images of baseline scan
• •No lung nodule(s) suggestive of lymphoma
• •No lung lesions suggestive of tuberculosis
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Blood glucose levels ≤ 150 mg/100 mL
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •Able to tolerate PET/CT imaging
• •No history of diabetes
• •No poorly controlled hypertension
• •No prior malignancy other than basal cell or squamous cell carcinoma of the skin, carcinoma in situ, or other cancer from which the participant has been disease free for \< 3 years
• •* No active malignancy within the past 5 years
• •PRIOR CONCURRENT THERAPY:
• •More than 5 years since prior chemotherapy or radiotherapy
• •No concurrent steroids